Experimental procedures for the subsequent extraction of lymphatic tissues to test lymphoid dendritic cell activation are described after treatment of an immunostimulating nanomaterial.
For evaluation of a new therapeutic agent for immunotherapy or vaccination, analysis of immune cell activation in lymphatic tissues is essential. Here, we investigated immunological effects of a novel lipid-DNA immunostimulant in nanoparticle form from different administration routes in the mouse: oral, intranasal, subcutaneous, footpad, intraperitoneal, and intravenous. These injections will directly influence the immune response, and harvesting lymphatic tissues and analysis of dendritic cell (DC) activation in the tissues are crucial parts of these evaluations. The extraction of mediastinal lymph nodes (mLNs) is important but quite complex because of the size and location of this organ. A stepwise procedure for harvesting the inguinal lymph node (iLN), mLN, and spleen and analyzing DC activation by flow cytometry is described.
Advances in immunology and nanomaterials have led to an abundance of potential new therapeutic strategies for applications in biomedicine, including drug delivery and immunostimulation. Optimization of the administration route is a vital aspect affecting the efficacy of immunostimulatory agents. An immunostimulatory nanoparticle (INP) consisting of DNA is a newly developed nano-immune adjuvant self-assembled by microphase separation because of the amphiphilic structure of lipid-DNA1. Therefore, protocols for INP involving administration of the material1 in vivo via different routes, and three procedures for harvesting appropriate tissues such as the inguinal lymph node (iLN), mediastinal LN (mLN), and spleen, are described. Finally, these tissues were analyzed for dendritic cell (DC) activation, the most powerful antigen-presenting cells in the immune system. This protocol can also be applied for evaluating antigens, antibodies, or other immune adjuvants2.
We tested the INP formulation because it is an agent that has shown great promise. INP is a Toll-like receptor 9 (TLR9) adjuvant material that contains nucleic acids, for which assessment of immunostimulation efficacy is required to test different injection methods3. In this context, the stimulation of DCs is a potent endpoint for in vivo evaluation. After antigen or immunostimulatory molecules are phagocytosed by DCs in the peripheral tissues or blood, these cells migrate to lymphoid organs such as the spleen and LNs4,5. Thus, DC activation was analyzed in the spleen, iLN, and mLN of the injected animals. Properly harvesting of these tissues is therefore also crucial for evaluating the immune response to a novel adjuvant or pathogens5. Such tissue harvesting is also important for developing a novel immunological methodology as a cancer therapy. Furthermore, this protocol can be used to verify the efficiency of other drugs, such as anti-human immunodeficiency virus therapeutics6.
All experimental procedures including animal handling, sacrifice, and organ isolation were performed in strict accordance with the rules of the International Animal Care and Use Committee at Shanghai Public Health Clinical Center and Asan Medical Center. The study protocol was approved by the respective committees on the Ethics of Animal Experiments at Shanghai Public Health Clinical Center (Mouse Protocol Number: SYXK-2010-0098) and Asan Medical Center (2016-02-168).
1. Preparation of Material
NOTE: A nano-adjuvant, INP, comprised of a self-assembled lipid-DNA carrier, namely U4T, and CpG-motif containing oligonucleotide, eCpG, was employed in the current study to test the appropriate injection route for immunotherapy and vaccination in mice2. Importantly, other potential therapeutic molecules such as antigens, antibodies, and adjuvant agents can be substituted for INP and tested using the same methodology described below.
2. General Animal Procedures
Note: Alternative methods for handling the mice can be used depending on the laboratory requirements and approved animal protocols8. The type of mice used is 6-week-old C57BL/6 and female mice.
3. Injection Routes
4. Isolation of Lymph Nodes and Spleen
Note: Use young and healthy lean mice (6 weeks old) for these procedures because the fats that typically build up around the lymph nodes in older mice are difficult to remove and can prevent proper visualization of the organ.
5. Preparation of samples for flow cytometry
Note: To assay the activation of DCs in the harvested iLN, spleen, and mLN, single-cell suspensions of these tissues are stained with fluorescence-conjugated antibodies as DC-specific markers, co-stimulatory molecules, and major histocompatibility complex molecules and analyzed by flow cytometry.
To evaluate appropriate injection routes of INP for lymphatic tissue DC activation, the DC population as lineage was defined as –CD11c+ cells in the spleen, iLN, and mLN and analyzed the expression levels of co-stimulatory molecules. Treatment of INP by subcutaneous (s.c.) and intravenous (i.v.) injection promoted substantial increases in CD40, CD80, and CD86 expression in the spleen and iLN DCs (Figure 2B and 2C). Footpad and intraperitoneal (i.p.) injection of INP also considerably up-regulated the expression levels of CD40, CD80, and CD86 in the spleen and iLN DCs compared to in the PBS-treated control (Figure 2B and 2C). In stimulated mLN DCs, intranasal (i.n.) injection of INP promoted the highest up-regulation of co-stimulatory molecules compared to that in the PBS-treated control (Figure 2D). i.p. and i.v. injection of INP also induced marked increases in co-stimulatory molecule expression in the mLN, while oral, s.c., and footpad injection of INP did not induce activation of mLN DCs (Figure 2D).
Figure 1: Location of intraperitoneal injection point Please click here to view a larger version of this figure.
Figure 2: Accurate location of intravenous injection Please click here to view a larger version of this figure.
Figure 3: DC activation in lymphatic organs analyzed by flow cytometry. C57BL/6 mice were injected with INP by six different injection routes and 24 h after injection, the spleen, iLN and mLN were harvested. (A) The DC population in the lymphatic tissue cells was defined as lineage –CD11c+ cells in live leukocytes. (B-D) The expression levels of CD40, CD80, and CD86 were analyzed by flow cytometry in the spleen (B), iLN (C), and mLN (D). Data are averages from the analyses of six independent samples. Results are expressed as the means ± standard error of the mean (SEM). The statistical significance of the differences between experimental groups was calculated using analysis of variance with unpaired Student's t-test. p-values<0.05 were considered significant. * <0.05, **<0.01. Please click here to view a larger version of this figure.
Many advances in nanotechnology and immunology have been achieved through therapeutic research of drug delivery and immunostimulation. Careful selection of the injection method is known to be important for immunostimulation, which was the focus of the present study.
Different injection routes were evaluated for a naturally non-toxic and biodegradable DNA-based material, INP (immunostimulatory nanoparticle), to determine which route yielded the best outcome. This approach is also relevant for delivering other therapeutic agents including antibodies, antigens, or other adjuvants.
To analyze the immune response to such injections, harvest of lymphatic tissue (spleen, iLN, and mLN) is required. Isolation of lymphatic tissues is the most crucial aspect of this protocol and required the use of a technique that has not been described previously in detail. Moreover, preparation of the single-cell suspension for further analyzing immune cells has not been well-described. This study focused on the extraction of the lymphatic tissues, particularly the iLN, mLN, and spleen, for analyzing DC activation. Systemic activation of the immune response mainly occurred through immune cells in the spleen. Additionally, the immune responses in the specific tissue were controlled by nearby lymph nodes. Evaluation of newly developed immune modulatory molecules should be conducted to determine whether the molecules can induce immune stimulation in the tissues. Therefore, the method for lymphatic tissue isolation and analysis of DC activation in the tissues can be used for newly developed immune stimulatory molecules.
To evaluate the immune stimulatory effect of INP, the iLN, mLN, and spleen were harvested and INP was shown to promote lymphatic DC activation. As determined previously, INP effectively targets TLR9 stimulation in DCs in mice2. Macrophages also express cytosolic TLR9 in mice. Therefore, INP injection may induce both DC and macrophage activation. However, macrophages reside in peripheral tissue that contribute to the phagocytosis of microbes in the tissue. Moreover, the antigen-presentation capacity and migratory effect to the lymphatic tissue of macrophages are comparably weaker than those in DCs. Therefore, evaluating the injection route of INPs for the immune stimulatory effect was suitable for examining DCs in the lymphatic tissue.
Therefore, the mode of immune adjuvant administration must be very carefully considered to achieve successful immunotherapy and vaccination using soft materials.
The authors have nothing to disclose.
This research was supported by Creative Materials Discovery Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017M3D1A1039421) and by Marine Biotechnology Program funded by the Ministry of Oceans and Fisheries, Republic of Korea and a grant (20150220).
Material | |||
phosphate buffer saline | Corning | 21-040-CVR | Washing organs |
(PBS, pH 7.4) | |||
isoflurane solution | Aesica Queenborough limited | 26675-46-7 | Anesthesia process |
Tuberculin 1mL syringe – | Junglim | N/A | Injection |
50 mL conical tube | S.P.L | 50050 | Anesthesia process |
1mL Insulin Syringe | (BD Ultra-FineTMII)_short needle | 324826 | Intramuscular Injection |
DMEM High Glucose | Hyclone | SH30081.01 | Storing organs |
Histopaque | Sigma-Aldrich | 10771 | FACS analysis |
Ethyl alcohol anhydrous 99.5 % | Daejung | 4022-4110 | Disinfectant |
Equipments | |||
FineCycler C100 (Thermocycler) | Ssufine | – | Anealing |
Centrifuge | Centrifuge | ||
FACS tube | FALCON | 2052 | FACS analysis |
Automated High-performance Flow Cytometer | BD (USA), FACSVerse | – | FACS analysis |